AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

December 18, 2020 GMT

WATERTOWN, Mass.--(BUSINESS WIRE)--Dec 18, 2020--

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 233,500 shares of Kala Pharmaceuticals common stock to forty-six new employees. The stock options were granted on December 15, 2020. The grants were approved by the Compensation Committee and were made as an inducement material to each employee entering into employment with Kala Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $7.63 per share, the closing price of Kala Pharmaceuticals’ common stock on December 15, 2020. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s new hire date and the remainder vesting in equal monthly installments over the following three years. Vesting of each option is subject to such employee’s continued service with Kala Pharmaceuticals through the applicable vesting dates.

ADVERTISEMENT

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY ® mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the October 2020 approval of EYSUVIS TM (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and the January 2019 launch of INVELTYS ® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.

View source version on businesswire.com:https://www.businesswire.com/news/home/20201218005004/en/

CONTACT: Investor Contacts:

Loraine Spreen

loraine.spreen@kalarx.com

857-277-4842Hannah Deresiewicz

hannah.deresiewicz@sternir.com

212-362-1200

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH SURGERY CLINICAL TRIALS PHARMACEUTICAL OPTICAL BIOTECHNOLOGY

SOURCE: Kala Pharmaceuticals, Inc.

Copyright Business Wire 2020.

PUB: 12/18/2020 04:01 PM/DISC: 12/18/2020 04:01 PM

http://www.businesswire.com/news/home/20201218005004/en